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AbstrAct
Introduction Meaningful patient engagement 
(PE) can enhance medicines’ development. 
However, the current PE landscape is 
fragmentary and lacking comprehensive 
guidance.
Methods We systematically searched for PE 
initiatives (SYNaPsE database/publications). 
Multistakeholder groups integrated these with 
their own PE expertise to co-create draft PE 
Quality Guidance which was evaluated by public 
consultation. Projects exemplifying good PE 
practice were identified and assessed against 
PE Quality Criteria to create a Book of Good 
Practices (BOGP).
Results Seventy-six participants from 
51 organisations participated in nine 
multistakeholder meetings (2016–2018). A 
shortlist of 20relevant PE initiatives (from 170 
screened) were identified. The co-created 
INVOLVE guidelines provided the main 
framework for PE Quality Guidance and was 
enriched with the analysis of the PE initiatives 
and the PE expertise of stakeholders. Seven 
key PE Quality Criteria were identified. Public 
consultation yielded 67 responses from diverse 
backgrounds. The PE Quality Guidance was 
agreed to be useful for achieving quality PE 
in practice, understandable, easy to use, and 
comprehensive. Overall, eight initiatives from 
the shortlist and from meeting participants 
were selected for inclusion in the BOGP based 
on demonstration of PE Quality Criteria and 
willingness of initiative owners to collaborate.
Discussion The PE Quality Guidance and BOGP 
are practical resources which will be continually 
updated in response to user feedback. They 
are not prescriptive, but rather based on core 
principles, which can be applied according 
to the unique needs of each interaction and 
initiative. Implementation of the guidance will 
facilitate improved and systematic PE across the 
medicines’ development lifecycle.
IntroductIon
The value and necessity of engaging 
patients during the development and 
life cycle of medicines is increasingly 
recognised1–3; many discrete programmes 
have been initiated,4–8 which are often 
specific to a particular phase of drug 
development (eg, clinical trials, regula-
tory or health technology assessment) and 
to a region.9–13 For example, in the USA, 
the Food and Drug Administration has 
conducted patient-focussed drug develop-
ment (PFDD) meetings to gather patient 
perspectives on specific conditions and 
their treatment more systematically.14 In 
Europe, the Innovative Medicines Initia-
tive has launched PARADIGM (Patients 
Active in Research and Dialogues for an 
Improved Generation of Medicines) to 
develop a framework for patient input in 
early dialogue, research priority setting 
and clinical trials design.15 Many more 
initiatives exist and though complemen-
tary, these separate activities have resulted 
in a fragmented PE landscape, with a lack 
of continuity, efficiency and coordina-
tion. Investment in a holistic, integrated 
and sustainable initiative is required to 
cover the entire medicines lifecycle and to 
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Figure 1 Process for development of Patient Engagement Quality Guidance (PEQG) tool.
connect all stakeholders across geographies. Though 
there is no widely accepted definition of patients’ 
engagement in the medicines’ development continuum, 
in this paper, the term ‘PE’ refers to the active and 
meaningful involvement of patients and carers as 
active participants and collaborators in developing 
medicines. Patient Focused Medicines Development 
(PFMD; www. pfmd. org) is a global multistakeholder 
collaboration of health stakeholders that aims to 
synergise PE efforts by working with stakeholders to 
co-create a meta-framework for PE that spans the 
entire medicines lifecycle. PFMD is taking a disci-
plined four-step approach to this co-creation, in order 
to build on existing work and prevent duplication. The 
steps are: (1) mapping and connecting the PE land-
scape to learn from existing efforts and identify needs 
or gaps; (2) convening multistakeholder workshops to 
co-create tools that meet identified needs; (3) reiter-
ative refinement of tools to develop and pilot a draft 
meta-framework for PE and (4) creation of a practical 
PE Actionable Framework and implementation tools. 
Here we describe the first two steps of the approach 
culminating in the development of the PE Quality 
Guidance which is a core element of the meta-frame-
work. The PE Quality Guidance was co-created as a 
practical tool to facilitate and improve the quality of 
PE activities across the medicines’ lifecycle. The prin-
ciples outlined within the PE Quality Guidance are 
intended to be applicable for use by any stakeholder 
involved in the design, execution or evaluation of PE 
activities (regardless of role, position, experience or 
geographical location) and relevant for all interactions 
of stakeholders with patients.
Methods
Landscape review and identification of priority needs in 
Pe
Multistakeholder Working Groups were established 
through invitation via PFMD and PFMD member 
networks, existing contributors to meta-framework 
co-creation activities and owners of PE initiatives. Invi-
tees were required to have some PE experience and 
expertise in at least one of the medicine development 
phases. A literature search was conducted to provide 
Working Group participants with an overview of 
the PE landscape. Published literature and existing 
frameworks were identified using keyword searches 
on PubMed and British Medical Journal (BMJ) Open 
(timeframe January 2011–December 2016). Keywords 
were PE, patient and public involvement, clinical 
trials, patients benefit, PE benefit for pharmaceu-
tical industry, PE benefit for patients, PE benefit for 
research. Articles relevant to PE in the context of 
medicines lifecycle that provided the most detail and 
granularity and were most informative for Working 
Group interrogation were identified.
SYNaPsE (SYNergising Patient Engagement) was 
used to augment published information available. 
SYNaPsE was designed as a platform for capturing PE 
practices and is a dynamic user-populated repository 
of objective, well-documented multistakeholder PE 
initiatives. It categorises and ‘maps’ PE initiatives and 
frameworks, organisations active in PE, experts and 
resources. Initiatives in SYNaPsE, follow a standard 
template for documentation of methods, challenges 
and outcomes, which gives a structure for under-
standing each initiative. Owners of relevant initiatives 
in SYNaPsE were contacted to provide more infor-
mation on their initiative(s) to capture a deeper level 
of insight and understanding that then informed the 
co-creation process. Each Working Group included 
participants with expertise in the relevant phase(s) 
of medicines development (figure 1): there was 
no overlap of individuals in the different Working 
Groups. Working Groups were tasked with using their 
PE experience and review of the PE landscape to iden-
tify and prioritise PE needs. Co-creation of practical 
PE Quality Guidance to help stakeholders improve 
the quality of their PE activities and provision of illus-
trative examples of good practice were identified as 
priorities independently across Working Groups.
Pe Quality Guidance co-creation
Task Forces comprised Working Group participants 
(or their nominees) who volunteered to contribute to 
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the iterative elaboration of the PE Quality Guidance, 
sharing their example PE initiatives and testing the PE 
Quality Guidance in development with these exam-
ples. Task Force nominees were invited based on their 
having the relevant expertise to complete prioritised 
actions and willingness and capacity to contribute. A 
Core Team comprising participants of Working Groups 
or Task Forces with extensive experience in PE was also 
established to facilitate finalisation of tools. There was 
intentional overlap with Working Group, Task Force 
and Core Team members to ensure continuity and 
incorporate learnings from each stage. A preliminary 
PE Quality Guidance tool was developed by Task Forces 
in an iterative process which included validation, feed-
back and refinement at each step, with input from the 
Working Groups (figure 1). The guidance introduces PE 
Quality Criteria to assess PE practices consolidated from 
published literature and co-developed further by Task 
Forces. The Quality Criteria were validated through 
retrospective application to real PE activity with feed-
back and refinement in an iterative process. Further 
feedback and validation were secured through public 
consultation.
Public consultation on draft Pe Quality Guidance
A public online, survey-based consultation on the 
draft PE Quality Guidance was undertaken (from 20 
November 2017 to 1 January 2018) to gather wider 
input from PE stakeholders. This consultation was open 
to all regardless of experience in PE. The survey had two 
sections: section one asked general questions about the 
PE Quality Guidance and its usability; section two asked 
detailed questions about the PE Quality Criteria specif-
ically (see online supplementary file 1 for Survey Ques-
tions). Consultation was invited via the PFMD website 
and across stakeholder groups via Working Group, Task 
Force and PFMD networks; and through advertising (21 
589 reach), media (40 259 reach) and a social media 
campaign. In addition, a separate focus group (organised 
and funded by Parkinson’s UK) with representation from 
patient organisations, a government health research 
agency, academic research, healthcare professionals and 
a regulatory agency was held in October 2017. Feedback 
was submitted for independent review by an external 
expert from the Working Group and a patient represen-
tative/academic from the Core Team to finalise the PE 
Quality Guidance.
development of the book of Good Practices
Examples of good practice were collected through 
screening of initiatives in SYNaPsE (entered between 
SYNaPsE launch in January 2017 and workshop 
commencement in September 2017) and via Task Force 
and PFMD networks. All initiatives independently 
submitted by PE initiative owners were eligible for 
inclusion in the Book of Good Practices. Preliminary 
selection criteria were pragmatic and included initia-
tives: being specific to PE in medicines’ development; 
involving more than one stakeholder group and having 
comprehensive description of methodology for PE 
practice (and outcomes for completed initiatives where 
available). Final selection for inclusion in the first itera-
tion of the Book of Good Practices was undertaken by 
the Core Team who reviewed each initiative against the 
following key criteria: being extensively described by the 
owner using the PE Quality Guidance; demonstrating 
PE Quality Criteria as assessed by majority consensus 
(>half) of the multistakeholder Core Team; focusing on 
involving patients in decision processes around medi-
cines development or lifecycle management; involving 
multiple stakeholder groups; owners/organisations 
agreeing to participate in the Book of Good Practices 
and being willing to provide additional information to 
further enrich the examples; being approved for public 
dissemination. The evaluation process was anonymised 
to avoid bias.
resuLts
summary of Pe Quality Guidance co-creation workshops
Nine Working Group, Task Force or Core Team meet-
ings were held (November 2016–June 2018) involving 
76 unique participants, representing 51 organisations 
(including patient charities, academic researchers, 
funders, pharmaceutical companies). Table 1 summarises 
objectives and outputs from these meetings.
Step 1: mapping and connecting the PE landscape to learn from existing 
efforts
Literature search yielded 239 results: 134 were available 
through PubMed, of which 12 were relevant or some-
what relevant to the subject and 105 through BMJ Open, 
of which 13 were relevant or somewhat relevant to the 
subject. Eight additional resources were identified and 
assessed to understand the progress of earlier developed 
approaches and concepts beyond the 2016 cut-off of the 
search period.1 6 7 16–20 The 33 relevant resources yielded 
seven conceptual frameworks/models (summarised 
in table 2). Although the importance of unifying PE 
approaches was highlighted within several models and 
frameworks, methodology gaps and variations were 
identified, for example, within objectives, outputs and 
applicability to different stages of medicines lifecycle. 
Working Groups agreed that taken together, the seven 
frameworks represented comprehensive tools that reflect 
the complexity of medicines research and development, 
and capture all stages of medicines lifecycle. They jointly 
demonstrated the following PE characteristics: diver-
sity and representativeness, joint working and partner-
ship, reciprocity, capabilities development and learning, 
continuity and sustainability, transparency, meaningful-
ness, metrics for impact assessment, standardisation and 
communication plans.
Step 2: Multistakeholder co-creation of PE guidance and good practice 
identification
Task Forces adapted and augmented the characteris-
tics and related indicators from the frameworks into 
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the PE Quality Guidance. The first section of the guid-
ance tool explains how to use it: for planning a new 
PE project; for gap analysis to compare projects within 
an organisation and to assess the impact of ongoing 
or completed PE projects. The INVOLVE recommen-
dations21–23 were agreed by Working Groups to be 
the most advanced, providing well documented and 
sufficiently detailed information (particularly on the 
practical ‘how to’ of PE) and were selected as the basis 
for development of the first iteration of PE Quality 
Criteria. The INVOLVE recommendations were 
developed for use in the UK and for advancing public 
involvement specifically in research and were therefore 
adapted and enriched with the analysis of PE initia-
tives collected in SYNaPsE and from Working Groups 
and Task Forces to reflect the needs of the broader PE 
community and stakeholders and to be relevant across 
all phases of medicines development. Seven PE Quality 
Criteria were agreed as a manageable number, compre-
hensive (without being overwhelming), relevant for 
the majority of PE stakeholders and accessible to all 
regardless of experience in PE. The PE Quality Criteria 
describe the core elements that should be integrated 
for individual PE initiatives or across several (related) 
initiatives that involve the same partners. They form 
the backbone of PE methodology and provide a set 
of basic principles to help standardise the levels of 
PE, assess the quality of PE in existing projects, and 
document and share outcomes in a standardised way. 
Descriptions for each of the seven PE Quality Criteria 
are summarised in table 3. Tools for assessment of 
initiatives (either planned, in preparation, ongoing or 
completed) against the PE Quality Criteria were also 
developed. Tools contain a definition, a rationale and 
questions for consideration by the initiative owners 
used for planning and/or evaluation purposes for each 
criterion.
examples of good practice
Of 170 available initiatives screened, 40 were selected 
based on preliminary criteria then shortlisted to 20 
using key criteria and anonymised for Core Team 
review. Eight initiatives were selected for inclusion 
in the first iteration of the Book of Good Practices. 
Table 4 provides a summary of the PE examples 
selected for the Book of Good Practices and results of 
their assessment using the PE Quality Criteria.
Pe quality guidance public consultation
The PE Quality Guidance public consultation resulted 
in 851 website visits and 67 responses from patients, 
patient advocates/organisations (n=25); pharmaceu-
tical and biotech industry (n=19); research/academia 
(n=12) and other (n=11). The majority (69%) of 
responders were from Europe and the remainder 
from Canada, the USA, Algeria and Australia. 
Over 80% of respondents indicated that they were 
‘advanced’ in terms of their PE experience (‘actively 
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table 3 Patient engagement (PE) quality criteria summary and description
Pe Quality Criterion* Brief description and rationale Practical illustrations†
1. Shared purpose Brief description: This refers to the importance of 
all stakeholders agreeing on the project’s aims and 
outcomes before starting the project.
Rationale: Early involvement is a key factor 
for quality of the process and includes the 
consideration of all perspectives in the early phase 
of planning.40
 ► The organisation worked with the research team and 
people affected by Parkinson’s to create a survey to 
consult a large patient population about attitudes to 
stem cell therapy.1
 ► A subset of survey respondents worked with the stem 
cell research team to explore and understand survey 
findings and were then invited to work as part of the 
research team to further develop the work and apply 
for funding.1
2. Respect and accessibility Brief description: This refers to (1) respecting each 
other, and respectful interactions within the project 
to be established among partners, and (2) openness 
to and inclusion of individuals and communities (to 
the project) without discrimination.
Rationale: A key quality aspect is the importance of 
securing a supportive culture that reflects that all 
stakeholders acknowledge the patients’ perspective 
as equally important to that of other professional or 
authoritative stakeholders.41 Practical steps must be 
taken to ensure access for all.42
 ► In the workshops we used moderators and verbal 
and nonverbal communication using for example 
pictures, as feelings may be better expressed with 
images.2
 ► We followed up in 1:1 meetings to clarify all 
individual perspectives and to understand if anything 
in the group was missed.2
 ► We created a process to provide access for patients 
who were not comfortable participating in a group 
setting and those with limited mobility.3
3. Representativeness of stakeholders Brief description: This refers to the mix of people 
involved, which should reflect the needs of the 
project, and the interests of those who may benefit 
from project outputs.
Rationale: Ensuring optimal representativeness is 
demanding but essential for any PE activity43 and 
involves careful consideration of the selection of 
patient representatives. For example, appointed 
patient representatives in committees may often be 
particularly resourceful relating to their disease and 
treatment, and it becomes important to consider 
how to ensure perspectives of less resourceful 
patients are considered.
 ► Different age groups, stages of disease, ethnicities 
and geographies were incorporated into the selection 
of patient/caregiver partners using a database of ~17 
000 patients and caregivers.3
 ► Members represent different socioeconomic 
backgrounds and diseases. Also, healthy young 
people are involved to ensure that they cannot have 
the bias of the disease and ensure that the general 
feedback is not connected with a specific condition.4
4. Roles and responsibilities Brief description: This refers to documentation 
of agreed and ideally co-created roles and 
responsibilities, indicating that all aspects of project 
needs will be established upfront and revisited 
regularly.
Rationale: Clarity on roles and responsibilities of 
all partners is essential for the implementation of 
equitable working practices that ensure PE opinions 
and expertise are respected and incorporated where 
possible into PE projects.
 ► Contracts were mutually agreed on and entered 
into up front—before the start of the projects—and 
modified as appropriate along the way.5
 ► Patients and caregivers were clear on their role in 
patient pathway mapping and how the data would 
be used. Patients and caregivers were also provided 
direction on how their input would be used with 
feedback loops built in throughout.3
 ► Commitment documents were developed with 
patients and caregivers.3
 ► Meetings and continued teleconferences were used 
to ensure that each member of the consortium 
knew what was expected and were accountable to 
everyone else.6
5. Capacity and capability for engagement Brief description: This refers to (1) capacity as 
having relevant and dedicated resources from all 
stakeholders and (2) capabilities for all stakeholders 
to enable meaningful engagement.
Rationale: It is essential that everyone has 
sufficient knowledge and skills to contribute 
effectively. This includes the professionals having 
sufficient PE knowledge and skills as well as 
patients having sufficient trials knowledge.
 ► Each patient/caregiver completed an assessment on 
their engagement preferences and received coaching 
during this (project) to ensure they were comfortable 
interacting with various stakeholders.3
 ► Training and tool kits have been developed for 
internal personnel, and external moderators are 
selected based on experience working with patients.5
 ► The patients involved had the requisite expertise 
as established advocates and included people 
with health communications expertise as well as 
experience as patients.7
Continued
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Pe Quality Criterion* Brief description and rationale Practical illustrations†
6. Transparency in communication and 
documentation
Brief description: This refers to the establishment 
of communications plan and ongoing project 
documentation that can be shared with 
stakeholders. Communication among stakeholders 
must be open, honest and complete.
Rationale: Transparent communications throughout 
the project both internally and externally is essential 
to ensure credibility of process and findings. 
Publication of protocols and results of all trials is 
increasingly recognised as essential for the effective 
and ethical evaluation of clinical products.44 45
 ► An involvement plan was developed for the project 
and shared. Other documentation shared between 
all stakeholders included: pre-read information; an 
immediate follow-up email detailing next steps; 
an intermediate follow-up document with interim 
findings. Further documentation will include long-
term follow-up (6–12 months).1
 ► Every month all patients were emailed for questions 
or updated with information.6
7. Continuity and sustainability Brief description: This refers to the smooth 
progression of the project and efforts to maintain 
relationships with stakeholders beyond a single 
project.
Rationale: Involvement of patients throughout the 
process as much as feasible, including aspects such 
as evaluation, dissemination and implementation 
can be very beneficial for the quality of the 
process.46 Additionally, ongoing commitment to PE 
and development of long-term relationships will 
enhance quality.
 ► Patient representative organisation recommended 
that further partnership working results in patients 
becoming part of the research team, co-applicants 
and co-authors.1
 ► All patients and caregivers that participated were 
kept abreast of development and continuous 
improvement of the initiative through electronic 
updates.3
 ► The plan included launch in two illness areas with the 
intent, if successful, for expansion beyond those areas 
and in additional. The team, including patient experts, 
has been involved in those discussions. A third illness 
area was launched, and more are planned.7
*Adapted from: National Standards for Public Involvement. Available at: http://www.invo.org.uk/wp-content/uploads/2018/06/Public_Involvement_
Standards_v1.pdf (Accessed 21 June 2018). Practical illustrations sourced from the Book of Good Practices (version 1). Available at: https://involvement-
mapping.patientfocusedmedicine.org/book-of-good-practices (Accessed 21 January 2019).
†The superscript numbers (1–7) following each practical illustration refers to the example number in the Book of Good Practices: 1, Example 6; 2, 
Example 7; 3, Example 4; 4, Example 8; 5, Example 1; 6, Example 3; 7, Example 2.
table 3 Continued
part of PE projects’), while 16% were a ‘beginner’ 
(‘currently I have no previous experience, but I am 
planning to do PE projects within the next year’) 
and, 3% ‘none’ (‘I have no experience in working 
with patients but would like to do more’).
Of 51 respondents, the vast majority (range 
85%–96%) agreed or strongly agreed that: the PE 
Quality Criteria are useful for achieving quality PE 
practice; the descriptive language used is compre-
hensive and easy to understand, and the format is 
clear. Overall, 56% of respondents felt they did not 
need help to use the PE Quality Guidance. Specific 
feedback included needing practical examples and 
specific tips based on how others have used it. Most 
respondents (range 65%–84%) agreed or strongly 
agreed that the PE Quality Guidance could be used 
to: improve the quality and consistency of PE activ-
ities; better plan and develop PE activities; better 
assess the quality and impact of PE initiatives; iden-
tify gaps and opportunities for PE activities; capture 
and share learnings beyond the project or project 
team and structure work with partnering organisa-
tions (figure 2).
Of 51 respondents, 86% agreed or strongly agreed 
that having practical PE guidance was important in 
their work and 90% indicated they would use such 
guidance. Almost half (49%) of respondents already 
use some type of PE guidance in their work. The 
vast majority (92%) of respondents believed that 
the PE Quality Guidance should be used by diverse 
health stakeholders (all those involved in medicines 
development, patients/patient organisations, phar-
maceutical industry, regulators, payers, research and 
academia). Specific feedback noted that US and EU 
standards for engaging patients and patient organ-
isations differ and should be recognised; the tool 
is a ‘shared guidance, understood and applied by 
all stakeholders’ involved in PE engagement and 
the tool may be especially useful for less experi-
enced patient representatives. Overall, 21 respon-
dents gave detailed feedback on the PE Quality 
Criteria including 85 comments on specific criteria 
and four general comments. Responses were gener-
ally evenly distributed across all seven PE Quality 
Criteria ranging from 67% (shared purpose) to 48% 
(respect and accessibility, representativeness of stake-
holders). Comments ranged from simple agreement 
(eg, ‘This is crucial’) to detailed suggestions on each 
criterion and were overall positive. The feedback 
from all partners, representing varying levels of PE 
experience, has informed the final versions of the 
PE Quality Guidance. We have created the Book of 
Good Practices to provide examples of good quality 
practical applications of the guidance.
dIscussIon
The development of the PE Quality Guidance 
adhered to the core principle of respect for all 
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Figure 2 Public consultation feedback on patient engagement (PE) quality guidance.
stakeholders’ knowledge. It also ensured a diversity 
of viewpoints from: a systematic search of the liter-
ature; a wide range of stakeholders co-creating the 
guidance (table 1) and public consultation, thereby 
minimising potential bias. This practical guide aims 
to improve PE quality during planning and devel-
opment of new medicine development projects or 
assess the quality and impact of ongoing/completed 
projects. Examples of good practice of the PE 
guidance were rated against the quality criteria to 
provide high-quality exemplars of PE in a range of 
contexts. This is not intended to be an exhaustive set 
of examples of how to apply the guidance, rather to 
provide real-world case studies showing the diver-
sity of approaches and techniques that can be used 
to generate meaningful PE. Finally, the PE Quality 
Guidance was assessed for utility and practicality 
by a wide range of stakeholders. They determined 
it would be of use, particularly to those new to PE 
and those wishing to document, and quality appraise 
their PE processes. In response to feedback, the PE 
Quality Guidance incorporates good practice exam-
ples and tips to aid practical implementation of PE 
across diverse activities and groups. The PE Quality 
Guidance is a dynamic tool and is currently being 
piloted and implemented across several PE initia-
tives. Learnings and feedback will be used to further 
refine the tool and we will report on the outcomes 
of these pilots.
PE is not ‘one size fits all’ and consequently, the 
PE Quality Guidance is not prescriptive, rather it is 
based on core principles that should be adapted and 
applied according to the unique needs of each inter-
action and project. These principles are relevant and 
applicable beyond medicines development specifi-
cally, for example, also in clinical research settings. 
The Guidance can be tailored by adding specific 
modules to deliver consistently high-quality PE activ-
ities. This modular approach facilitates a long-term 
strategy for more systematic and meaningful PE. 
We hope the detailed specificity of the PE Quality 
Guidance and supporting Book of Good Practices 
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provides not only sufficient structure to allow 
genuine engagement but also sufficient flexibility to 
be adapted to many types of medicines development, 
cultural considerations, national legislation and rele-
vant specific circumstances. We also believe—and 
our survey confirmed—that the guidance principles 
have sufficient generalisability to also be applied to 
the development of other clinical interventions, such 
as educational interventions and medical devices.
We acknowledge potential limitations of this 
work: literature screening may not have identi-
fied all relevant existing efforts, and differences in 
Working Group individuals’ experience, confidence 
and specific challenges (such as language barriers 
and health conditions) may influence participation 
during workshops. However, different processes and 
checkpoints were established to ensure that all partic-
ipants were able to contribute fully (eg, anonymously 
if desired). Though there were limited contribu-
tions from participants in developing countries, the 
distribution of contributors reflects current activity 
patterns across medicines development. Further-
more, our extensive search of literature for PE 
guidance effectively expanded the pool of contrib-
utors to the PE Quality Guidance tool. As such, we 
believe our guidance is as comprehensive and diverse 
as is possible. The resulting first iteration of the PE 
Quality Guidance intentionally focuses on PE char-
acteristics that are relevant across stakeholder groups 
to be broadly relevant. The next phase of develop-
ment involves customisation of the Guidance in 
identified priority activities. Examples for the Book 
of Good Practices were primarily identified through 
SYNaPsE: some initiatives (though worthy) may not 
have included sufficient information to meet initial 
inclusion criteria. As the PE Quality Guidance is used 
by research projects worldwide, it will also serve to 
collect good practices which will be published on the 
PFMD website to inspire new initiatives.
The need for PE that informs medicine develop-
ment at all stages of the development process has 
been widely recognised. It is known that mean-
ingful PE can improve the relevance of medicines in 
addressing symptoms of importance to patients and 
improve health outcomes.24–26 It could help address 
the observation that current medical research does 
not optimally address the needs and concerns of 
patients and the clinicians that treat them.27 28 
However, it is important that this PE is genuine and 
not tokenistic in order to realise the potential bene-
fits.29 30 The field of PE is growing and maturing and 
use of evidence-based methodologies and documen-
tation is becoming increasingly important.31 32 The 
PE Quality Guidance provides a much-needed global 
tool for documenting and improving the quality of 
the process of PE across the medicines’ lifecycle and 
subsequently, the quality of desired outputs. Future 
uses should seek to apply scientific and robust 
methodologies to further refine the guidance and 
build the evidence base for the value of systematic 
PE.
We described the methodological four-step 
approach towards co-creation of a pilot meta-frame-
work for PE: this requires multistakeholder, long-
term investment in a global and collaborative 
venture. Investment in a foundation of mutual 
respect and trust through transparent governance, 
in building and synergising the PE ecosystem, and 
in driving implementation of co-created solutions to 
deliver better PE. The co-creation of this meta-frame-
work and implementation toolkit (Steps 3 and 4) is 
underway and will build on outcomes from piloting 
the PE Quality Guidance and ongoing feedback to 
provide a comprehensive and actionable resource for 
more consistent and meaningful PE.
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